Search results
Results from the WOW.Com Content Network
Apply to your State Pharmaceutical Assistance Program (SPAP) for older adults if there is one and you qualify. Thirteen states, mostly in the Northeast, have SPAPs that help pay prescription-drug ...
Plavix is marketed worldwide in nearly 110 countries, with sales of US$6.6 billion in 2009. [45] It was the second-top-selling drug in the world in 2007 [46] and was still growing by over 20% in 2007. US sales were US$3.8 billion in 2008. [47] Before the expiry of its patent, clopidogrel was the second best-selling drug in the world.
In 2006, Sanofi-Aventis SA and Bristol-Myers Squibb Co., the producers and patent owners of Plavix, the blood thinner drug, settled a patent lawsuit with Apotex. [23] [24] In the settlement, Apotex agreed not to sell a generic version of Plavix until September 2011, in exchange for an unspecified amount of money. [23]
ADAP Advocacy is an American national 501(c)(3) non-profit organization based in Washington, D.C., that is dedicated to promoting and enhancing the AIDS Drug Assistance Programs (ADAPs) and improving access to care and treatment for Persons Living with HIV/AIDS (PLWHA) in the United States and the U.S. Territories.
For premium support please call: 800-290-4726 more ways to reach us
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Metabolism of ticlopidine, clopidogrel and prasugrel to an active metabolite. Clopidogrel is a prodrug that is metabolized by two pathways. In one of the pathway most of the dose of clopidogrel (85%) is hydrolyzed by esterases to an inactive carboxylic acid derivate and rapidly cleared via glucoridination followed by renal excretion.
An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation.